Background: Toxicity associated with chemotherapy is a major therapeutic challenge and is caused by chemotherapy-induced DNA damage and inflammation. We have recently reported that cell-free chromatin (cfCh) fragments released from dying cells can readily enter into healthy cells of the body to integrate into their genomes and induce DNA double-strand breaks, apoptosis and inflammation in them. We hypothesized that much of the toxicity of chemotherapy might be due to release of large quantities of cfCh from dying cells that could trigger an exaggerated DNA damage, apoptotic and inflammatory response in healthy cells over and above that caused by the drugs themselves.
Introduction
Fifteen million new cases of cancer are detected globally each year [1] , the majority of whom receive some form of chemotherapy and suffer varying degrees of its toxic side-effects. Chemotherapy-induced toxicity results from systemic DNA damage and inflammation of healthy cells [2] [3] [4] . Symptoms of toxicity include bone marrow suppression, sore mouth, nausea and vomiting, diarrhoea, loss of appetite, fatigue, hair loss, sterility and nerve damage [5] . Several antidotes are usually prescribed to mitigate the toxic symptoms of chemotherapy with varying degrees of success [5] . We have recently reported that cell-free chromatin (cfCh) released from dying cells can readily enter into healthy cells of the body to integrate into their genomes to induce DNA double-strand breaks apoptosis and inflammation in them [6, 7] . We show here that chemotherapy-induced toxicity can be traced to these findings in that most of the toxic side-effects of chemotherapy are caused by cfCh released from dying cells. The initial round of chemotherapy-induced cell death triggers a cascading effect whereby the dead cells release more cfCh causing further rounds of DNA damage, apoptosis and inflammation thereby exaggerating or amplifying the toxic effects of chemotherapy. We also show that chemo-toxicity can be largely prevented by cfCh neutralizing/degrading agents administered concurrently with chemotherapy.
Methods Institutional Animal Ethics Committee approval
The experimental protocol was approved by the Institutional Animal Ethics Committee of Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India and experiments were carried out according to the Committee's animal safety guidelines.
Chemotherapy drugs and dosage
The chemotherapy drugs used in this study were: adriamycin (10 mg/kg), cyclophoshamide (100 mg/kg), cisplatin (20 mg/kg), methotrexate (25 mg/kg) and paclitaxel (10 mg/kg). All drugs were administered as a single i.p. dose.
Preparation of cfCh neutralizing/degrading agents
Pullulan-histone antibody nanoconjugates (CNPs) were synthesized as described by us earlier except that we exclusively used H4 IgG for preparing CNPs [6, 8] . We have shown that CNPs specifically bind to chromatin fragments and inactivate them both in vitro and in vivo [6, 8] .
DNase I. Bovine pancreatic DNase I was obtained from Sigma-Aldrich (Catalogue No. DN25-1G).
Resveratrol-copper (R-Cu). Resveratrol (R) is a plant polyphenol which has been widely investigated for its antioxidant properties [9] . We and others have shown that R acts as a pro-oxidant in the presence of copper (Cu) by its ability to reduce Cu (II) to Cu (I) thereby generating a free radical [10, 11] . Because of this pro-oxidant property, R-Cu can degrade genomic DNA [12] , and this pro-oxidant property is retained even when the molar concentration of Cu is reduced more than 10 000-fold with respect to that of R [12] . The detailed methodology for preparing R-Cu for in vitro and in vivo experiments is given in supplementary materials, available at Annals of Oncology online.
Isolation of cfCh from mouse serum and assessment of biological activity
The method for cfCh isolation from serum has been described by us in detail earlier [6] . Biological activity of the isolated cfCh [6] was ascertained by treating NIH3T3 mouse fibroblast cells with the cfCh isolates (10 ng of DNA) and analysing the activation of H2AX, active caspase-3, NFjB and IL-6 at 6 h by indirect immunofluorescence as described earlier [6, 7] . Detailed methodology for isolation of cfCh from mouse serum and assessment of biological activity is given in supplementary materials, available at Annals of Oncology online. The list of sources and catalogue numbers of the primary and secondary antibodies used is given in supplementary Table S1 , available at Annals of Oncology online.
Estimation of serum cfCh and inflammatory cytokines following adriamycin treatment
Serum cfCh was estimated using the Cell Death Detection ELISA PLUS kit (Roche Diagnostics GmbH, Mannheim, Germany) [6] and Statistical comparison was carried out using unpaired Student's t-test. * ¼ p < 0.05; ** ¼ p < 0.01; *** ¼ p < 0.001; **** ¼ p < 0.0001.
Assessment of neutropenia
Detailed methodology for assessing neutropenia is given in supplementary materials, available at Annals of Oncology online.
Survival analysis
Forty animals were divided into 4 groups of 10 mice each and all groups received a lethal dose of adriamycin (20 mg/kg). CNPs, DNase I and R-Cu were administered in doses and frequencies as described above. Survival between groups was compared by Kaplan-Meier survival analysis using log-rank test.
Results
Since we had earlier demonstrated that cfCh isolated from serum of human subjects can phosphorylate H2AX and active caspase-3 [6] , we first investigated whether mouse cfCh was also capable of activating DNA damage and apoptosis when added to cells in culture. We also examined whether mouse cfCh could, in addition, activate inflammatory cytokines. Figure 1 and supplementary Figure S1 , available at Annals of Oncology online, show that addition of 10 ng DNA equivalent of cfCh isolated from mouse serum when added to NIH3T3 cells caused an approximately threefold increase in activities of cH2AX, active caspase-3, NFjB and IL-6 at 6 h. All these activities could be neutralized by simultaneous addition of cfCh neutralizing/degrading agents namely, CNPs, DNase I and R-Cu (P < 0.0001). We next examined whether cfCh neutralizing/degrading agents namely, CNPs, DNase I and R-Cu could prevent the systemic release of cfCh and inflammatory cytokines into the circulation following a single injection of adriamycin. We first determined the time-point when the maximum surge of cfCh and inflammatory cytokines occurred following adriamycin challenge (10 mg/ kg) (supplementary Figure 2A and B, available at Annals of Oncology online). In case of cfCh, we observed two peaks occurring at 6 and 18 h, while in case of inflammatory cytokines (IL-6), we observed a single peak that occurred at 18 h. We chose the 18 h time-point for our experiments using the cfCh inhibitors. We injected mice with adriamycin (10 mg/kg) with and without concurrent treatment with CNPs, DNase I and R-Cu and collected blood samples by orbital puncture at 18 h. The marked rise in serum cfCh that occurred following adriamycin injection could be completely neutralized by concurrent treatment with the three cfCh neutralizing/degrading agents ( Figure 2A ) (P < 0.001). We also observed a marked rise in inflammatory cytokines CRP, IL-6, IFN-c and TNF-a following adriamycin challenge. These could be significantly inhibited by CNPs, DNase I and R-Cu ( Figure  2B ) (P < 0.01-0.0001).
We next examined whether CNPs, DNase I and R-Cu could prevent tissue DNA damage and inflammation following administration of 5 different chemotherapy agents namely, adriamycin, cyclophosamide, cisplatin, methotrexate and paclitaxel. A single dose of adriamycin induced remarkable cellular activation of H2AX, active Capsase-3, NFjB and IL-6 in lung, liver, heart, brain, ovary, skin and small intestine ( 0.04 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Figure 3 . Prevention of cellular DNA damage (cH2AX), apoptosis (active caspase 3) and inflammation (NFjB and IL-6) in various tissues following a single i.p. injection of adriamycin by concurrent treatment with CNPs, DNase I and R-Cu. Estimation of cH2AX and active caspase-3 were done at 24 h whereas NFjB and IL-6 were estimated at 72 h. The bars represent mean values 6 SEM of five animals in each group. Statistical comparison was carried out using unpaired Student's t-test. **P <0.01; ***P <0.001; ****P <0.0001.
agents could reduce the activated levels of the tissue parameters to those obtained in control animals (supplementary Table S2 , available at Annals of Oncology online). These data show that cfCh neutralizing/degrading agents could inhibit adriamycininduced DNA damage, apoptosis and inflammation indicating that cfCh were responsible for inducing these cellular pathologies.
With respect to the other chemotherapy agents namely, cyclophosamide, cisplatin, methotrexate and paclitaxel, we restricted our investigation to the study of activation of H2AX and NFjB in brain and PBMCs ( Figure 4A-D and supplementary Figures S4A-D, available at Annals of Oncology online). All four chemotherapeutic agents induced DNA damage and inflammation in brain and PBMCs, albeit to varying degrees (P < 0.05 to <0.0001). However, in each case, the administration of CNPs, DNase I and R-Cu concurrently with the respective chemotherapeutic agents caused significant reduction in the activation of these parameters (P < 0.05 to <0.0001). , methotrexate (C) and paclitaxel (D) by concurrent treatment with CNPs, DNase I and R-Cu. All animals were sacrificed at 72 h except in case of the cH2AX-cisplatin experiment wherein animals were sacrificed at 24 h. The bars represent mean values 6 SEM of five animals in each group. Statistical comparison was carried out using unpaired Student's t-test. *P <0.05; **P <0.01; ***P <0.001; ****P <0.0001.
We next examined the effect of CNPs, DNase I and R-Cu in preventing neutropenia caused by adriamycin. A single injection of the drug (10 mg/kg) induced a significant reduction in total leukocyte count that reached a nadir at 24 h and remained low for several days ( Figure 5A-C) . Concurrent administration of CNPs, DNase I and R-Cu prevented neutropenia to a great extent throughout its course. Values at most time-points, with a few exceptions, were statistically significant (P < 0.05 to <0.0001).
Finally, we show that death from a lethal dose of adriamycin (20 mg/kg) could be prevented or delayed by concurrent administration of cfCh neutralizing/degrading agents ( Figure 6 ). All animals in the control (adriamycin alone) group died by day 6, whereas 50% and 30% of animals treated with R-Cu and DNase I, respectively, survived (P < 0.0001 and P < 0.05, respectively). With respect to the group of mice treated with CNPs, although all animals ultimately died, their survival was significantly prolonged (P < 0.01). 
Discussion
It is the current belief that toxic side-effects of chemotherapyinduced systemic cellular DNA damage and inflammation are entirely caused by the drugs themselves. However, a puzzle relating to chemotherapy toxicity has remained unaddressed; this is, while the half-life of most chemotherapeutic agents is around 24 h [5] , their toxic effects last for several days. For example, bone marrow suppression following chemotherapy reaches a nadir around 7-14 days and sore mouth is at its worst between 5 and 14 days [5] . For these reasons, chemotherapy cycles are usually spaced at 3-weekly intervals to allow for tissue recovery to occur. Our results suggest a different mechanism underlying chemotherapy toxicity. They suggest that the cellular damage and inflammation that are directly attributable to chemotherapy drugs are marginal and that most of the toxic side-effects of chemotherapy are induced by cfCh released from the initial round of drug-induced cell death triggering a cascading effect whereby dead cells release more cfCh causing further rounds of DNA damage, apoptosis and inflammation thereby exaggerating or amplifying the toxic effects. This proposal helps to explain why the duration of toxic effects of chemotherapy are disproportionally prolonged compared with the half-life of the drugs themselves.
In confirmation of our earlier report using cfCh isolated from serum of human subjects [6] , we demonstrate that cfCh isolated from mouse serum can also activate cH2AX and active caspase 3 when added to cells in culture (Figure 1 , upper two panels and supplementary Figure S1 , available at Annals of Oncology online, upper two panels). Although inflammation is a major side-effect of chemotherapy, the mechanism by which chemotherapyinduced inflammation is triggered is poorly understood [2, 13] . We show that cfCh are directly responsible for inducing inflammation and that the activation of pro-inflammatory cytokines NFjB and IL-6 can be abrogated by concurrent treatment with cfCh degrading/neutralizing agents ( Figure 1 , lower two panels and supplementary Figure S1 , available at Annals of Oncology online lower two panels).
We demonstrate that CNPs, DNase I and R-Cu can virtually abolish tissue DNA damage, apoptosis and inflammation resulting from chemotherapy. There was remarkable suppression of these toxic pathologies in all tissues examined namely, lung, liver, heart, brain, ovary, skin small intestine and PBMCs (Figures 3  and 4) . cfCh release from dying cells following chemotherapy treatment appears also to be responsible for bone marrow suppression. The prolonged neutropenia following a single injection of adriamycin which lasted for 8-10 days supports our hypothesis that the initial round of cell death inflicted by adriamycin caused a cascading effect whereby cfCh released from the initial round of cell-death catalysed several further rounds of cfCh-induced cell death resulting in a prolonged neutropenic effect. In any event, we show that neutropenia could be prevented to a great extent by concurrent administration of CNPs, DNase I and R-Cu. Finally, we show that the above agents can prevent adriamycin induced lethality thereby implicating cfCh in causing death of mice following high-dose chemotherapy.
It is likely that suppression of DNA damage, apoptosis and inflammation by cfCh neutralizing/degrading agents is affected at two levels. The first is mediated via a reduction in the blood levels of cfCh (Figure 2A and B) , while the second is mediated at a cellular level wherein cfCh released from dying cells are neutralized/ degraded and prevented from inducing damaging effects on bystander living cells. In support of the latter proposal, we have recently shown that cfCh from dying cells can activate DNA damage and inflammation in surrounding cells and that these could be prevented by cfCh neutralizing/degrading agents both in vitro and in vivo [7] .
It could be argued that the agents that we have used to neutralize/degrade cfCh may themselves be responsible for inactivating the cytotoxic drugs thereby suppressing their toxic side-effects. This is unlikely for two reasons: first, CNPs, DNase I and R-Cu have different chemical compositions and modes of action with respect to cfCh inactivation. It is unlikely that these three agents will have same drug inactivating action. Second, we have used five different cytotoxic drugs each one with a different mode of action. It is again improbable that CNPs, DNase I and R-Cu, which themselves have different modes of action, will interfere with the diverse pathways involved in induction of cytotoxic effects of five disparate drugs.
Our results have significant clinical implications. They suggest that cardiac, gastro-intestinal, neurological, cutaneous and reproductive side-effects of chemotherapy which include cardiac failure, nausea, vomiting, diarrhoea, neuro-toxicity, sterility and hair-loss can be potentially prevented by administration of cfCh neutralizing/degrading agents administered concurrently with chemotherapy. Similarly, bone marrow suppression and the resultant neutropenia as well as the occasional fatality resulting from chemotherapy may also appear to be preventable. If our results are successfully translated in to the clinic, it might Figure 6 . Survival of mice treated with a single lethal dose of adriamycin with and without concurrent treatment with CNPs, DNase I and R-Cu. Comparison between groups was conducted by Kaplan-Meier survival analysis using log-rank test. Control versus CNPs (P < 0.01); control versus DNase I (P < 0.05); control versus R-Cu (P < 0.0001) (n ¼ 10 mice in each group).
